Meningococcal Disease
62
0
0
57
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
45 trials with published results (73%)
Research Maturity
57 completed trials (92% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 62 trials
100.0%
+13.5% vs benchmark
45%
28 trials in Phase 3/4
79%
45 of 57 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 57 completed trials
Clinical Trials (62)
Understanding the Immune Response to Two Different Meningitis Vaccines
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia
Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)
Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B
Hepatitis B Vaccination in Infants
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
PRIME Follow up - Quadri Meningo Vacinees
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
South Australian Meningococcal B Vaccine Herd Immunity Study
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents